Seres therapeutics presents late-breaking data from ser-109 phase 3 ecospor iii study in recurrent c. difficile infection at idweek2021

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced late-breaking data from its phase 3 ecospor iii study evaluating ser-109, an investigational oral microbiome therapeutic for recurrent c. difficile infection (rcdi). ser-109 was associated with significantly greater reduction of antimicrobial resistance genes (args) compared to placebo, with the reduction observed both rapidly (by week 1) and sustained through w
MCRB Ratings Summary
MCRB Quant Ranking